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Adjuvanted whole inactivated virus (WIV) influenza vaccines show promise as broadly
protective influenza vaccine candidates. Using WIV as basis we assessed the
relative efficacy of different adjuvants by carrying out a head-to-head comparison of
the liposome-based adjuvants CAF01 and CAF09 and the protein-based adjuvants
CTA1-DD and CTA1-3M2e-DD and evaluated whether one or more of the adjuvants
could induce broadly protective immunity. Mice were immunized with WIV prepared from
A/Puerto Rico/8/34 (H1N1) virus intramuscularly with or without CAF01 or intranasally
with or without CAF09, CTA1-DD, or CTA1-3M2e-DD, followed by challenge with
homologous, heterologous or heterosubtypic virus. In general, intranasal immunizations
were significantly more effective than intramuscular immunizations in inducing
virus-specific serum-IgG, mucosal-IgA, and splenic IFNγ-producing CD4T cells.
Intranasal immunizations with adjuvanted vaccines afforded strong cross-protection with
milder clinical symptoms and better control of virus load in lungs. Mechanistic studies
indicated that non-neutralizing IgG antibodies and CD4T cells were responsible for the
improved cross-protection while IgA antibodies were dispensable. The role of CD4T
cells was particularly pronounced for CTA1-3M2e-DD adjuvanted vaccine as evidenced
by CD4T cell-dependent reduction of lung virus titers and clinical symptoms. Thus,
intranasally administered WIV in combination with effective mucosal adjuvants appears
to be a promising broadly protective influenza vaccine candidate.
Keywords: whole inactivated virus (WIV) influenza vaccines, liposome-based adjuvants, protein-based adjuvants,
cross protection, non-neutralizing serum antibodies, CD4T cells
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INTRODUCTION
Vaccination is the cornerstone for the prevention of influenza
(1). Current influenza vaccines predominantly mediate strain
specific protection by eliciting neutralizing antibody responses
to the globular head region of hemagglutinin (HA), one of the
surface glycoproteins of the virus. They do not provide protective
immunity against strains not included in the vaccine (1, 2).
New virus strains regularly emerge through antigenic drift, the
phenomenon responsible for recurrent epidemics. Moreover,
zoonotic influenza virus subtypes pose a serious pandemic threat,
as exemplified by pandemic H1N1(2009) and the potentially
pandemic subtypes H5N1, H7N9, H10N8, or H5N6 (3–6). There
is therefore an urgent need for broadly protective influenza
vaccines which can prevent or at least mitigate infection by virus
strains not included in the vaccine.
Whole inactivated virus (WIV) vaccines contain all the
structural viral proteins and retain the conformation of native
virus particles and as such make a promising basis for an
influenza vaccine. Moreover, WIV has an intrinsic ability to
activate innate immune responses, e.g., antigen presenting cells
via Toll-like receptor 7 (TLR7) signaling (7). Although WIV
was the first vaccine to be used, it was later replaced by split
and subunit vaccines that were considered safer (8), despite
WIV being superior at inducing immune responses in mice and
naïve human beings (7, 9–12). Interest has recently refocused on
WIV vaccines as studies have shown them capable of inducing a
certain degree of cross-protection upon parenteral and mucosal
vaccination (3, 13–16). However, a large amount of antigen was
required to achieve protection and/or virus challenge was only
performed shortly after immunization in these studies (16). One
approach to reduce the dose of WIV needed would be to use
adjuvants that might also improve the breadth of the immune
responses (17–19).
There are various adjuvants under investigation for improving
the immunogenicity of influenza vaccines (20). In this study,
we compared the liposome-based adjuvants CAF01 and CAF09
and the protein-based adjuvants CTA1-DD and CTA1-3M2e-
DD. These adjuvants were chosen because they were previously
used successfully with several vaccine candidates, including
influenza vaccines and are ready for or currently evaluated
in clinical trials (21–38). The cationic adjuvant formulations,
CAF01 and CAF09, are liposomes consisting of N,N′-dimethyl-
N,N′-dioctadecylammonium (DDA) as delivery vehicle. For
CAF01, α,α′-trehalose 6,6′-dibeheneate (TDB) acts as an
immunomodulator and liposome-stabilizer, while CAF09 is
stabilized and adjuvanted with monomycoloyl glycerol (MMG)-
1 and contains the TLR3 ligand Poly(I:C) as an additional
immunomodulator (21, 24). CAF01 and CAF09 have been
shown to generate strong T cell and antibody responses, with
particularly high IgG2a responses for CAF01 (21, 22, 37). CAF09
is furthermore capable of inducing potent CD8+ T cell responses
against protein and peptide based antigens (24, 33, 37, 38).
CAF01 can be administered parenterally while CAF09 is mainly
administered intraperitoneally (i.p.,). However, there has been a
number of studies which showed promising results when CAF09
was given mucosally (Christensen et al. unpublished data).
Furthermore, CAF05, a predecessor adjuvant was successfully
administered via mucosal route (39). This motivated us to
administer CAF09 via intranasal route. CTA1-DD is a fusion
protein consisting of the enzymatically active A1 subunit of
cholera toxin and a dimer of an Ig binding element from
Staphylococcus aureus protein A. It targets cells of the innate
immune system which results in strongly enhanced humoral and
cellular immune responses (27–29). Contrary to whole cholera
toxin the mucosal CTA1-DD adjuvant is safe and non-toxic as
found in non-human primates and it does not accumulate in the
olfactory bulb and nerve following administration intranasally
(i.n.) and, hence, cannot cause Bell’s palsy (40). CTA1-3M2e-DD
harbors an insert of three copies of the exterior domain of the M2
protein of influenza virus, M2e (26, 30).
We compared these adjuvants head-to-head to assess
their relative potency in stimulating cross-reactive and cross-
protective anti-influenza immunity in mice. In order to mimick
the situation of antigenic drift and antigenic shift, mice
were immunized intramuscularly (i.m.) or i.n. with A/Puerto
Rico/8/34 (PR8)WIVwith or without the different adjuvants and
2 weeks after the final immunization mice were challenged with
homologous PR8, heterologous (H1N1)pdm09 or heterosubtypic
X-31 (H3N2) virus to assess protection and several immune
parameters. We observed that WIV administered i.n. with the
mucosal adjuvants conferred much stronger cross-protection
than parenterally administered WIV with or without adjuvant.
Studies into the significance of different immune mechanisms
for protection revealed that non-neutralizing serum antibodies
and CD4T cells were important for cross-protection while
IgA, even when present in high levels, did not play a
critical role. Thus, WIV administered i.n. in combination
with effective mucosal adjuvants provided the strongest cross-
protection against heterosubtypic influenza virus infections and




Live influenza viruses PR8 (H1N1), A/California/7/2009
(H1N1)pdm09, and X-31 (H3N2) (a reassortant strain carrying
the HA of A/Aichi/2/68 and the internal proteins of PR8) were
propagated in embryonated chicken eggs and were titrated
on MDCK cells and in CB6F1 mice. Whole inactivated virus
vaccines (WIV) were prepared from these viruses by inactivation
with beta-propiolactone. Beta-propiolactone was removed in
down-stream processing by concentration of the allantoic fluid
and purification using sucrose gradient centrifugation. The WIV
HA content (µg/ml) was determined by using Lowry protein
assay and SDS-PAGE (colloidal blue staining) to establish total
protein content and percentage HA, respectively, the HA content
was then calculated. Quality and quantity of HA were confirmed
by single radial immunodiffusion assay (41).
Adjuvants
The liposomal adjuvants CAF01 and CAF09 were produced as
described previously (42). The dose for both adjuvants was 300
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µg per 50 µl for i.m. and 300µg per 40µl for i.n. administration.
The protein adjuvants, CTA1-DD and CTA1-3M2e-DD, were
produced by MIVAC Development AB, Sweden. The latter
construct carried three copies of the extracellular domain of the
influenza virus M2 protein (SLLTEVETPIRNEWGSRSNDSSD).
Briefly, the fusion proteins were expressed in E. coli DH5 cells,
transformed with the expression vector for the fusion protein,
and grown in 500ml cultures overnight in SYPPG medium
with 100 ug/ml carbenicillin, at 37◦C, as previously described
(30). Endotoxin levels were below 100 EU/mg as verified by
use of the Endosafe R© testing system (Charles River). For both
protein adjuvants, the concentration was 5 µg per 40 µl WIV.
Filtered Dulbecco’s phosphate buffered saline containing CaCl2
and MgCl2 (DPBS, GIBCO by Life Technologies
TM) was used as
a diluent.
Animal Experiments
All animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of Groningen
(IACUC-RUG, DEC 6923), or the Central Committee for Animal
Experiments CCD of the Netherlands (AVD105002016599),
the Animal Welfare and Ethics Review Body (AWERB) of
the National Institute for Biological Standards and Controls
(NIBSC), Potters Bar, UK (PPL 80/2537), or the IACUC of the
University of Gothenburg, Sweden.
Adjuvant Comparison Study
Female CB6F1/OlaHsd (C57Bl/6 x BALB/c F1) mice aged 6–
8 weeks were purchased from Envigo (The Netherlands). The
mice were distributed randomly and housed in groups of six
within individually ventilated cages (IVC) at the animal facility,
receiving standard water and diet. Group sizes were determined
using Piface software aiming at a power of 80%. Mice were
vaccinated three times with 0.5 µg HA of PR8 (with or without
the adjuvants) on days 0, 10, and 20 as described in Table 1.
Mice from groups 1–3 received 50 µl PBS or vaccine i.m., 25
µl per hindlimb. Mice from groups 4–7 received respective
vaccines i.n. in a volume of 40 µl, divided between the two
nostrils. Vaccination and virus challenge were carried out under
Isoflurane/O2 anesthesia. Three weeks after the 3rd vaccination
(day 41), six mice from each group (of 18) were sacrificed to
determine vaccine-induced immune responses. The remaining
mice were challenged with 104.4 TCID50/mouse of homologous
PR8 virus, 103.3 TCID50/mouse of heterologous (H1N1)pdm09
or 105.5 TCID50/mouse of heterosubtypic X-31 (titers were
chosen on the basis of titration experiments in CB6F1 mice).
Six mice from each experimental group were sacrificed on day 3
post challenge to assess protection against virus replication in the
lungs. The remaining six mice were observed until day 10 post
challenge to assess clinical symptoms such as weight loss, ruﬄed
fur and activity. The humane endpoint was set to a loss of >20%
of the original weight from the day of challenge. Additionally,
for the mechanistic experiments, a score sheet was used to follow
the animals. Parameters such as weight loss, appearance (degree
of ruﬄed fur, hunched back) and behavior of the animals (slow
movements, difficulty in walking, circling, response to external
stimulus) were recorded. These parameters were given scores
from 1 to 4 for least to most severe. A cumulative score for a given
day of 10 was considered to be the humane endpoint.
Adoptive Serum Transfer
Serum samples were collected from mice mock-immunized
with PBS, or immunized with PR8 WIV i.n., WIV+ CAF09
or WIV+CTA1-3M2e-DD as described above. Two hundred
microliter of pooled sera were administered i.p. to naïve
mice. Mice were then challenged with 105.5 TCID50/mouse of
heterosubtypic X-31 virus 1 day post adoptive transfer. Mice
from positive control group received serum samples from mice
immunized with PR8 WIV and were challenged with PR8 live
virus. Animals were followed for 14 days and clinical symptoms
were assessed using the scoring system described above.
CD4T Cell Depletion
Anti-CD4 antibody (200 µg/injection, clone GK 1.5 Bioceros,
Utrecht, The Netherlands) was used for in vivo CD4 depletion,
which was assessed by staining with FITC-labeled anti-CD4
(clone RM 4.4, Thermo Scientific). Female CB6F1 mice (aged
6–8 weeks) were immunized as described above (groups 1, 4, 5,
7 from Table 1) followed by a heterosubtypic challenge with X-
31 virus (105.5 TCID50/mouse). Mice were injected i.p. with the
anti-CD4 antibody 1 day before, 1 and 7 days after challenge.
Six animals/group were sacrificed on day 3 post challenge for
assessment of lung virus titers while the remaining animals were
followed for 14 days for clinical symptoms using the scoring
system described above.
IgA Knockout Experiment
IgA knock-out mice (IgA KO; BALB/c background, males and
females) were obtained fromMargaret Conner, Baylor College of
Medicine, Houston, TX, US and bred at EBM in Gothenburg,
Sweden. The mice were immunized as described in Table 1,
groups 1, 4, 5, and 7 and challenged with X-31 virus on day
41. Female BALB/c mice were used as wild-type (wt) controls.
Clinical symptoms were assessed for 14 days using the scoring
system described earlier.
Sample Collection From Mice
Before sacrifice, blood was drawn by cheek puncture for
determining IgG, IgA and neutralizing antibody titers. Nasal and
lung washes were taken using 1ml PBS (pH 7.4) with Complete R©
protease inhibitor cocktail (Roche, Almere, The Netherlands) for
determining IgA titers. Lungs were collected in 1ml complete
EPISERFmedium (100U/ml penicillin, 100mg/ml streptomycin,
12.5ml of 1M HEPES, 5ml of 7.5% sodium bicarbonate
for 500ml medium, Thermo Fisher Scientific, Bleisweijk,
Netherlands) for determination of viral load. Spleens were
collected in 1ml Iscove’s Modified Dulbecco’s Medium (IMDM)
(Thermo Fisher Scientific, Bleisweijk, Netherlands) containing
10% v/v FBS (Lonza, Basel, Switzerland), 100 U/ml penicillin, 100
mg/ml streptomycin and 50µM 2-mercaptoethanol (Invitrogen,
Breda, The Netherlands) to assess cellular immune responses.
Lung Virus Titration
Virus titration was performed as described previously (43).
Briefly, the lungs were homogenized in 1ml EPISERF
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TABLE 1 | Vaccination and challenge scheme.
Groups Vaccine









1 PBS i.m. – – 50
2 WIV i.m. 0.5 – 50
3 WIV+ CAF01 i.m. 0.5 300 50
4 WIV i.n. 0.5 – 40
5 WIV+ CAF09 i.n. 0.5 300 40 A/PR/8/34
6 WIV+ CTA1-DD i.n. 0.5 5 40 (H1N1)pdm09
7 WIV+ CTA1-3M2e-DD i.n. 0.5 5 40 X-31
medium and centrifuged at 1,200 rpm for 10min to
collect the supernatant. These supernatants were used to
infect MDCK cells with serial 2 fold dilutions of the lung
supernatants to determine lung virus titers as described before
(43). Viral titers are presented as log10 titer of 50% tissue
culture infectious dose per gram of lung. Limit of detection
(LoD) was determined by calculating the log10 of the 1st
dilution and the negative values were given half the value
of the LoD.
Assessment of Antibody Responses
Titers of influenza-specific IgG, IgG1, IgG2a, IgA, anti-NP, anti-
M2e and neutralizing antibodies were determined in blood
serum samples taken on day 41, i.e., the day of challenge. IgA
was determined in mucosal samples immediately after sample
collection. ELISAs were performed as described previously
using WIV prepared from each of the challenge viruses,
subunit vaccine (SU) prepared from X-31, NP protein, or M2e
protein for coating (44). To determine whether the serum
antibodies were (cross-)neutralizing, microneutralization (MN)
assays were performed using infectious PR8, (H1N1)pdm09
or X-31 virus as described previously (45). LoD for IgG
was determined by calculating the log10 of the 1st dilution
while LoD for MN titers was calculated using Log2 of the
1st dilution.
Multifunctional T Cell Assay.
To assess the contribution of influenza-specific T cells in
protection, a multifunctional T cell assay was performed
which involved staining for intracellular cytokines IFNγ, TNFα,
IL2, and IL4 expressed by CD3+CD4+ and CD3+CD8+ T
lymphocytes. All reagents, buffers and antibodies were purchased
from eBioscience, The Netherlands.
Spleens collected in IMDM were immediately processed and
single cell suspensions were obtained using GentleMACS C
tubes and GentleMACS dissociator (Miltenyi Biotec, Leiden,
The Netherlands). Cell suspensions were then forced through
a cell strainer (BD Bioscience, Breda, The Netherlands) and
erythrocytes lysed using ACK lysis buffer (0.83% NH4Cl,
10mM KHCO3, 0.1mM EDTA). Cells were re-stimulated
with a final concentration of 10µg/ml PR8, (H1N1)pdm09
or X-31 (H3N2) WIV plus 10µg/ml of NP366 peptide,
ASNENMETM for PR8, ASNENVETM for (H1N1)pdm09 or
ASNENMDAM for X-31 (University Medical Center Leiden,
The Netherlands) in the presence of co-stimulatory anti-
CD28 antibody for 16 h. For each mouse, non-stimulated
control cells were used to measure the baseline expression
of the cytokines. After 12 h of incubation, protein transport
inhibitor (Thermo Scientific, Netherlands) was added to
stop the transport of proteins out of the Golgi apparatus.
Cell stimulation cocktail containing PMA-ionomycin (Thermo
Scientific, The Netherlands) was used as a positive control
stimulant. Next day, cells were washed once with FACS
buffer and stained for surface markers (anti-CD3-Alexa-fluor
700, anti-CD4-FITC, anti-CD8a PerCP-efluor720, all purchased
from Thermo Scientific, The Netherlands) for 45min at 4◦C,
followed by rinsing with cold PBS and staining with the
fixable viability dye eFluor 780 for 30min at 4◦C. After two
washes with FACS buffer, cells were fixed with fixation buffer
and then permeabilized with FACS permeabilization buffer
(Thermo Scientific). For intracellular cytokine staining (ICS),
antibodies (anti-IFNγ-PE-Cy7, anti-IL2-PE, anti-TNFα eFluor
450 and anti-IL4 APC, Thermo Scientific) were added to the
cells and incubated for 45min. Ultracomp beads (Thermo
Scientific, The Netherlands) were used to prepare compensation
controls. Events were acquired on an LSRII flow cytometer
(BD Biosciences) and FlowJo software (Tree Star) was used
for analysis.
Statistics
For statistical analysis of intracellular cytokine levels, the
numbers of cytokine positive and cytokine negative cells
in the stimulated cell populations were compared with
paired unstimulated controls using MIMOSA (Mixture
Models for Single-Cell Assays) for IFNγ, TNFα, IL2
and IL4 (46). A false discovery rate of q ≤ 0.01 was
accepted. A Chi-Squared test was used to compare the
number of responders between groups. P ≤ 0.05 were
considered significant.
The non-parametric Mann-Whitney U test was used to
test if the differences between two groups with respect to
different parameters were significant. A p < 0.05 was considered
significant. Significance is represented as ∗p < 0.05, ∗∗p <
0.01, ∗∗∗p < 0.0001. Statistical analyses were performed using
GraphPad Prism version 5 for Windows (GraphPad Sofware, La
Jolla, California, USA www.graphpad.com).
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RESULTS
WIV Combined With Mucosal Adjuvants
Provides Best Cross-Protection
In order to determine the relative efficacy of WIV vaccines
combined with different adjuvants, mice were vaccinated three
times via the most suitable route of administration with
WIV derived from PR8 virus alone or mixed with CAF01,
CAF09, CTA1-DD or CTA1-3M2e-DD, followed by challenge
with homologous PR8, heterologous H1N1pdm09 (same virus
subtype as PR8 but different strain) or heterosubtypic X-31
(different virus subtype but same internal viral proteins). To
assess the protective efficacy of the tested vaccines, challenged
mice were observed for weight loss and clinical symptoms for a
period of 10 days or until they reached defined humane endpoint.
Percent weight loss was calculated (Figures 1A–C) and survival
curves were plotted (Figures 1D–F). Furthermore, to assess
viral loads in the lungs, mock vaccinated and WIV vaccinated
animals were sacrificed 3 days after homologous, heterologous or
heterosubtypic virus challenge (Figures 1G–I).
When infected with PR/8 virus, all mock immunized mice
reached the defined humane endpoint (>20% weight loss) and
were sacrificed by day 6 post challenge. In contrast, mice from
all groups immunized three times with WIV, with or without
adjuvants, were protected from weight loss post challenge with
homologous PR8 virus (Figures 1A,D). Furthermore, all but one
(with low titer) of the vaccinated mice were completely protected
from virus replication in the lungs (Figure 1G).
Challenge with heterologous (H1N1)pdm09 virus resulted
in gradual weight loss in mock immunized animals gradually
necessitating euthanasia on day 6 or 7 post infection. Animals
vaccinated with non-adjuvanted WIV i.m. showed some weight
loss but all survived until the end of the study. Surprisingly,
mice immunized i.m. with CAF01 adjuvanted vaccine lost more
weight and 2 out of 6 mice had to be sacrificed (Figures 1B,E).
Animals vaccinated with WIV i.n. exhibited little weight loss
except for one animal which reached the humane endpoint
on day 5 post challenge. Mice vaccinated with WIV plus
mucosal adjuvants presented the best cross-protection against
heterologous virus challenge: they showed little or no weight loss
and all animals survived to day 10 post challenge (Figures 1B,E).
Although not significant, lung virus titers were somewhat
higher in well protected than in unprotected, mock-immunized
mice (Figure 1H).
In the heterosubtypic X-31 challenge experiment, all animals,
whether vaccinated or not, initially showed a similar trend in
weight loss (Figure 1C). However, from day 3 onwards, all the
mice immunized mucosally with adjuvanted WIV recovered.
In contrast, mock-immunized, parenterally immunized and
mice immunized i.n. with WIV alone continued to lose
weight and most animals had to be sacrificed, except for
4 out of 6 mice immunized i.m. with non-adjuvanted
WIV (Figure 1F). Only mice mucosally immunized with
adjuvanted WIV demonstrated significant reduction in lung
viral titers as compared to mock-immunized control mice.
CTA1-DD and CTA1-3M2e-DD adjuvanted vaccines afforded
the largest reduction in lung viral titers (Figure 1I). Thus,
i.n. immunization with CAF09, CTA1-DD or CTA1-3M2e-
DD adjuvanted WIV stimulated significantly broader protection
compared to systemic immunizations with WIV alone or WIV
plus i.m. CAF01 adjuvant.
Immuno-Profiling Reveals Strong
Correlation Between Survival and Serum
Antibodies, Mucosal IgA and IFNγ+ CD4
T Cells
To determine which immune mechanisms correlated with the
observed cross-protection and to what degree these mechanisms
would differ for the different adjuvanted vaccines, various
immunological assays were performed. Sera, nasal and lung
washes were collected 3 weeks after the 3rd immunization
for antibody titer assessments, while T cell responses against
heterologous (H1N1)pdm09 and heterosubtypic X-31 virus were
determined using spleens of vaccinated animals 3 days post
heterosubtypic challenge. The results of immunoprofiling for
the heterologous and heterosubtypic challenge experiments are
summarized as heatmaps (Figures 2A,B) to reveal patterns which
correlate with protection; the individual data can be found in the
Supplementary Information (Figures S1–S5).
Immunization with PR8 WIV i.m. reliably induced
neutralizing antibodies against the homologous virus, especially
when administered with adjuvant (Figure S1A). By contrast,
i.n. immunizations poorly stimulated neutralizing antibodies,
even in the presence of adjuvants. Importantly, we found no
neutralizing antibodies against heterologous (H1N1)pdm09 or
heterosubtypic X-31 virus irrespective of the immunization route
or adjuvant used (Figures 2A,B and Figures S1B,C). However,
all immunized mice developed serum IgG antibodies reactive
with homologous, as well as heterologous and heterosubtypic
virus and these titers were of identical magnitude for all three
virus strains (Figures 2A,B and Figures S1D–F). The addition
of adjuvants to i.m. and i.n WIV immunizations enhanced
cross-reactive serum IgG resulting in similar endpoint titers.
CAF01 and CAF09 affected IgG titers most strongly and
enhanced both IgG1 and IgG2a. CTA1-DD and CTA1-3M2e-DD
were comparatively less effective in stimulating IgG and IgG1
and had only minor effects on IgG2a levels (Figures 2A,B
and Figures S2A,B).
Furthermore, we wanted to identify the antigens targeted by
the cross-reactive IgG. Use of subunit vaccine for coating revealed
that vaccine-evoked, cross-reactive antibodies readily bound to
viral surface proteins. These antibodies were found in all mice
immunized i.m., but were present in mice immunized i.n. only
when adjuvanted vaccine was used (Figures 2A,B, Figure S2C).
Anti-NP antibodies were detected only in mice vaccinated with
WIV plus CAF01 and one mouse from the WIV plus CAF09
group (Figures 2A,B and Figure S2D). Anti-M2e antibodies
were induced only by WIV adjuvanted with CTA1-3M2e-DD
(Figures 2A,B and Figure S2E). Vaccination, especially when
done with adjuvanted vaccines, therefore induced cross-reactive
antibodies which mainly targeted the viral surface proteins. The
levels of these antibodies correlated with protection from severe
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FIGURE 1 | Adjuvanted i.n. administered vaccine provides best protection. CB6F1 mice were vaccinated thrice 10 days apart with PBS, non-adjuvanted or
adjuvanted WIV vaccines. Three weeks after the last vaccination, 6 mice/group were challenged with homologous PR8 (H1N1) (A,D,G), heterologous
A/California/7/2009 (H1N1)pdm09 (B,E,H) or heterosubtypic X-31 (H3N2) viruses (C,F,I). Six animals/group were followed for 10 days for weight loss (A–C) and
survival (D–F). Three days post challenge 6 mice/group were sacrificed for determining lung viral load (G–I). Groups are represented as in Table 1: 1: PBS, 2: WIV
i.m., 3: WIV+CAF01 i.m., 4: WIV i.n., 5: WIV+ CAF09 i.n., 6: WIV+ CTA1-DD i.n., 7: WIV+ CTA1-3Me-DD i.n. Dashed line indicates Limit of detection (LoD)
(G–I). Virus titers are represented as log10 titers/gram of lung tissue with level of significance as *p < 0.05 and **p < 0.01 calculated using Mann-Whitney U-test.
disease, except in the group with CAF01-adjuvanted vaccine
delivered i.m.
Determination of influenza specific mucosal IgA revealed that
mice from the PBS control group as well as mice immunized i.m.
with non-adjuvanted or CAF01-adjuvanted WIV developed no
or very low mucosal IgA responses (in nose and lungs) against
any of the viruses (Figures 2A,B and Figures S3A,B,C). In
contrast, all miceimmunized i.n. with adjuvanted WIV produced
significant levels of specific IgA antibodies in both nose and lungs
against all three virus strains, and these levels were significantly
higher than in mice immunized i.n. with non-adjuvanted WIV.
Therefore, mucosal immunization in the presence of adjuvant
was required for successful induction of cross-reactive mucosal
IgA (Figures 2A,B and Figures S3A,B,C). IgA titers strongly
correlated with protection from weight loss (Figures 2A,B).
We next assessed vaccine-induced T cell responses. In vitro re-
stimulation of splenocytes with heterologous or heterosubtypic
WIV demonstrated that mice immunized i.m and mice
immunized i.n. with non-adjuvanted WIV developed no or very
low levels of IFNγ-producing CD4T cells. Mice immunized
i.n. with adjuvanted WIV demonstrated enhancement of IFNγ-
producing cells, with CTA1-3M2e-DD being most potent. In
addition to IFNγ, we also measured IL2 and TNFα responses
in CD4+ T cells, but although restimulation with WIV
and peptides increased the numbers of T cells producing
these cytokines, the percentages were low and no significant
differences between immunized and mock-immunized animals
were observed (results not shown). The large majority of vaccine-
specific CD4T cells produced IFNγ, while very few cells were
multifunctional, also producing other cytokines (Figure S5). In
contrast to CD4+ T cells, CD8+ T cells were not induced
in significant numbers by any of the vaccines (Figures 2A,B
and Figures S4C,D). In conclusion, IFNγ-producing CD4T cells
were the only T cell population induced and their numbers
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FIGURE 2 | Immunoprofiling against heterologous and heterosubtypic viruses. Animals were vaccinated 3 times with the vaccines indicated in Table 1. After 3
vaccinations, sera, nasal, and lung washes and spleens were collected to determine systemic, mucosal and cell mediated immune responses (n = 6). Some animals
were challenged with heterologous (A) and heterosubtypic (B) virus to determine protection, lung viral load (n = 6) and survival (n = 6). Generated data was used as
input and conditional formatting was performed in Ms Excel to plot heatmaps. Each column represents one animal. Survival is shown with different color scheme as
these are different animals compared to the rest. Dark blue indicates worst survival while light blue indicates best survival. For other parameters, heatmaps range from
red (lowest response) to green (best response).
were enhanced significantly by adjuvantedWIV administered i.n.
Protection from weight loss correlated well with the number of
IFNγ-producing CD4T cells (Figures 2A,B and Figures S4A,B).
Dissecting the Mechanisms of Protection
From the heat maps it can be deduced that animals which
were completely protected from heterosubtypic challenge had
high levels of serum IgG and mucosal IgA and high numbers
of IFNγ-producing CD4T cells. We next performed a series
of experiments in order to determine whether any of these
factors was critical for protection from heterosubtypic virus
infection. For these experiments we focused on CAF09 and
CTA1-3M2e-DD as the most successful adjuvants from the
previous experiment and used PBS and non-adjuvanted WIV
as controls.
To assess if serum antibodies can mediate cross-protection,
mice were passively immunized via the i.p. route with serum
collected from animals which had been mock-immunized with
PBS or immunized with WIV, WIV+CAF09 or WIV+CTA1-
3M2e-DD i.n. One day later they were challenged with
heterosubtypic X-31 virus. Animals which received PR8 immune
serum followed by a homologous challenge with PR8 virus served
as positive control group. Mice were observed daily for clinical
symptoms using the score sheet described previously. We found
that PR8 immune serum completely protected mice against PR8
virus infection. Serum from mice immunized i.n. with PR8 WIV
without adjuvant did not provide protection against infection
with heterosubtypic X-31 virus and the mice transfused with
this serum exhibited high clinical scores and reduced survival
(Figures 3A,B). By contrast, serum from mice immunized with
WIV plus CAF09 or CTA1-3M2e-DD protected partially and
clinical scores were reduced by 50% compared to unimmunized
control mice. Thus, non-neutralizing serum IgG antibodies from
mice immunized i.n. with CAF09 or CTA1-3M2e-DD adjuvanted
WIV appeared to partially protect against heterosubtypic X-31
virus challenge.
Next, we studied the role of CD4+ T cells in protection.
Depletion of CD4T cells was achieved through anti-CD4 Mab-
treatment of mice and resulted in reduction of CD4T cell
numbers in peripheral blood by >95% (data not shown). We
found that CD4 depletion did not affect survival (Figures 4A–D)
or clinical scores (Figures 4E–H) upon X-31 virus infection in
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FIGURE 3 | Serum antibodies induced by mucosally adjuvanted WIV might induce cross-protection. Serum was collected from animals vaccinated thrice with PBS
i.n., non-adjuvanted WIV i.n., WIV+ CAF09 i.n., or WIV+ CTA1-3M2e-DD i.n. and was administered passively in naïve mice (n = 6) via the i.p. route. One day after
passive immunization animals were challenged with heterosubtypic X-31 virus. Animals from the positive control group received PR8 immune sera and were challenged
with homologous PR8 virus. The mice were followed for survival (A) and clinical symptoms (B) assessed using a score based on weight, appearance and behavior.
the well immunized animals. Yet, CD4T cell depletion had a
significant effect on lung virus titers in animals immunized
with WIV and CTA1-3M2e-DD while all other immunization
protocols showed comparable lung virus titers irrespective of
CD4 depletion (Figure 4I). Therefore, CD4T cells appeared to
play a role in protection against heterobsubtypic challenge only
in the CTA1-3M2e-DD group.
Finally, we addressed whether cross-reactive local IgA
antibodies impacted on protection against infection in the
mice immunized i.n. by repeating the immunization/challenge
experiment in IgA KO mice. In line with reports in literature,
we found that mock-immunized IgA KO mice were more
susceptible to influenza infection than mock-immunized wt
BALB/cmice, demonstrated by higher clinical scores and survival
post challenge (47). Wild-type BALB/c mice immunized with
non-adjuvanted WIV demonstrated reduced clinical scores as
compared to non-immunized BALB/c mice but this was not the
case for IgA KO mice indicating a role for IgA in protection
(Figures 5A,E and Figures 5B,F). When immunized with WIV
and any of the mucosal adjuvants, wt and IgA KO mice
developed protective immunity and survived the challenge
infection (Figures 5C,D,G,H). Clinical scores of IgA KO mice
immunized with CAF09 adjuvanted vaccine were higher than
those of wt mice (Figure 5G). Mice immunized with CTA1-
3M2e-DD adjuvanted WIV developed the lowest clinical scores
with little difference between wt and IgA KO mice (Figure 5H).
These results suggest that local IgA antibodies exerted some
protection from severe disease but were not critical for survival
in this model.
DISCUSSION
In this study, we compared liposome and protein adjuvants
head-to-head to assess their relative efficacy in inducing cross-
reactive immunity in mice, when combined with i.m. and i.n.
administered WIV. In addition, we dissected which immune
parameters contributed to protection and to what extent
these would be vaccine-specific. The results indicate that i.n.
administered WIV combined with a mucosal adjuvant provided
enhanced cross-protection compared to WIV administered i.m.
with or without adjuvant and non-adjuvantedWIV administered
i.n.. We observed that non-neutralizing serum IgG, mucosal IgA
and IFNγ-producing CD4T cells were significantly higher for
mice immunized i.n. with WIV plus adjuvant than for the other,
less well protected groups. While non-neutralizing serum IgG
antibodies and CD4T cells were contributing to protection, our
experiments in IgA KO mice were less conclusive, but there
was a trend toward a protective effect of local IgA on the
clinical symptoms.
Mucosal immunization has been shown to be superior
to parenteral immunization for stimulating local immunity
and resident memory T cells in the lung (48–50) and to
provide cross-protection against heterosubtypic virus challenge
(14, 51). In agreement with these studies, we found that i.n.
immunization with adjuvanted WIV afforded stronger cross-
protection than parenteral immunizations. This was the case even
though serum anti-viral IgG levels appeared quite comparable
for mice immunized i.m. or i.n. with adjuvanted vaccines.
Upon heterologous infection with (H1N1)pdm09 virus, clinical
symptoms and survival correlated poorly with virus replication
in the lungs while for heterosubtypic infection with X-31 virus
we observed a clear correlation between clinical scores and lung
virus titers. We chose day 3 to assess the lung viral load because
we wanted to check if the vaccination has any impact on the
replicating virus at a stage where the replication is at peak which
in mice is on day 3 (52, 53). From experience we assume that in
successfully immunized mice virus titers resolved more quickly
than in mock immunized mice (45).
Adjuvanted WIV vaccines induced significantly higher
systemic immune responses compared to non-adjuvanted WIV.
Interestingly, the levels of serum IgG antibodies reacting with
homologous, heterologous and heterosubtypic WIV in ELISA
assays were similar, suggesting that most of the IgG antibodies
induced by immunization with WIV were cross-reactive. This is
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FIGURE 4 | CD4 depletion does not affect protection but affects virus growth. Mice (n = 12/group) were vaccinated thrice i.n. with PBS (A,E), non-adjuvanted WIV
(B,F), WIV+ CAF09 (C,G) or WIV+ CTA1-3M2e-DD (D,H) followed by heterosubtypic challenge. On day−1, 1 and 7 relative to the challenge, anti-CD4 antibody or
PBS was administered i.p.. Mice were followed for 14 days for survival (A–D) and clinical symptoms (E–H). Dotted lines in E-H indicate the humane endpoint. Six
animals/group were sacrificed on day 3 post challenge to determine lung virus titers (I). LoD is indicated by dashed line. Mock depletion is presented by filled symbols
with—and CD4 depletion is represented by open symbols with +. Virus titers are represented as log10 titers /gram of lung with level of significance as *p < 0.05
calculated using Mann-Whitney U-test.
in line with recent observations in humans that also indicate that
many influenza-specific antibodies, whether measured before or
after vaccination, are cross-reactive (54, 55). Although serum
antibodies induced by adjuvanted WIV were cross-reactive they
could not neutralize heterologous and heterosubtypic virus in
vitro, which was according to expectations (45, 56). Nevertheless,
when transferred to naïve animals these antibodies provided
partial protection against X-31 challenge. It has been shown that
anti-influenza antibodies can mediate cross-protection via non-
neutralizing mechanisms such as antibody dependent cellular
cytotoxicity (ADCC), antibody dependent cellular phagocytosis,
or complement mediated cytotoxicity (CDC) (57–60). Which of
these mechanisms, if any, is involved in protection afforded by
WIV adjuvanted with CAF09 or CTA1-3M2e-DD remains to
be elucidated.
Vaccination with WIV plus mucosal adjuvants also led to
remarkably enhanced levels of cross-reactive local IgA in the
lungs and nose of mice. IgA has been shown to be more
cross-reactive than IgG (61, 62). Moreover, Maurer et al have
recently shown that IgA antibodies can also neutralize influenza
virus in an antigen-aspecific manner by providing sialic acid
in the glycosylated Fc part which serves as a decoy receptor
not only for influenza virus but also for other viruses using
sialic acid as a receptor (63). However, in our study adjuvanted
WIV administered i.n. completely protected IgA KO mice from
reaching the humane endpoint post heterosubtypic challenge,
similar to wt BALB/c mice, indicating that IgA was not crucial
for protection. Nevertheless, we cannot exclude that local IgA
antibodies exerted some protective function, as reflected in the
higher clinical scores in immunized and challenged IgA KOmice
compared to the wt mice. Whether local IgA plays a role in
cross-protection induced by adjuvanted WIV administered i.n.
or not is controversial. For example, Zhang et al. (64) showed that
i.n. immunization with a CTB/CT-adjuvanted subunit vaccine
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FIGURE 5 | IgA antibodies are not critical in cross-protection. IgA KO mice and BALB/c mice were vaccinated thrice i.n. with PBS (A,E), non-adjuvanted WIV
(B,F), WIV+CAF-09 (C,G) or WIV+CTA1-3M2e-DD (D, H) followed by heterosubtypic challenge. The mice were followed for survival (A–D) and development of
clinical symptoms (E–H) for a period of 14 days. IgA KO mice are represented by dashed lines with open symbols while BALB/c wt mice are represented by solid lines
with filled symbols. Dotted lines indicate humane endpoint.
stimulated equally efficient control of virus growth in wt and IgA
KO mice. Yet, using mice deficient in the poly Ig receptor and
thus unable to transport IgA across the respiratory epithelium,
Asahi et al demonstrated that mucosal IgA is critical, in particular
for protection from heterologous virus challenge (65). From
our observations, we think that mucosal IgA, though not being
crucial on its own, works in concert with other mechanisms to
provide the observed cross-protection.
IFNγ-producing cross-reactive CD4 positive T cells increased
significantly upon mucosal vaccination, especially in mice
immunized with WIV plus CTA1-3M2e-DD. This could be due
to the fact that M2e contains an MHC class II restricted CD4
helper epitope (26). CD4 depletion shortly before and after
challenge did not affect survival, but impaired the control of lung
virus growth in animals vaccinated with WIV plus CTA1-3M2e-
DD, indicating a role of CD4T cells in controlling virus growth
rather than controlling clinical symptoms and in turn survival.
CAF09-adjuvanted WIV did not induce significant numbers of
CD4T cells and accordingly, depletion of CD4T cells during
infection did not affect clinical scores or lung virus titers.
We did not observe IFNγ-producing CD8T cells induced
by vaccination. This was somewhat unexpected since at least
CAF01, CAF09, and CTA1-DD are known to support induction
of CD8T cells (24, 33, 37, 66). Failure to detect CD8T cells in
our experiments might be because they were indeed absent or
because we missed them due to the timing of the experiments.
We assessed CD8T cell responses on day 25 after the last
immunization, by which time the cells were already through the
retraction phase and the numbers might therefore have been
too low to detect. Furthermore, we used intracellular cytokine
staining, a method which allows simultanous determination of
multiple cell populations and cytokines but is not as sensitive as
ELISPOT assay for the detection of CD8T cells. Despite the fact
that we did not find them, we cannot categorically rule out that
CD8T cells contributed to protection. It is known that lung tissue
resident memory (TRM) CD8T cells have an important role in
protection from influenza infection (66, 67). These cells might
indeed have been induced in our experiments, but as parts of
the lungs had to be used for other purposes and the remaining
tissues were insufficient for isolating the required numbers of
lymphocytes, we were unable to investigate them. Follow up
studies will address this issue.
Although WIV plus CAF01 induced the highest levels of
cross-reactive antibodies, mice in the respective experimental
group showed severe clinical symptoms and reduced survival
post challenge. One thing which distinguished the CAF01
vaccinated mice group from the other groups was the induction
of anti-NP antibodies. In a pre-clinical study in pigs by Ricklin
et al. NP vaccination produced a strong immune response
but induced lung inflammation and immunized pigs were not
protected (68). In murine models the situation is not entirely
clear. Although it has been shown that anti-NP antibodies can
confer resistance to influenza virus infection (69–72) (contrary
to our results), a previous study from our group demonstrated
that mice vaccinated with NP adjuvanted with MPLA (which
developed NP-specific antibodies) showed more rapid weight
loss in the initial phase of infection than mock vaccinated mice
(73). Furthermore, animals receiving a virosomal vaccine without
NP showed fewer signs of illness compared to mice receiving a
virosomal vaccine with NP.
One of the limitations of the study is the use of X-31
virus for heterosubtypic challeng. X-31 is a ressortant between
PR8 and A/HK/68 and thus contains internal genes derived
from PR8 virus. In future studies it would be ideal to
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use a wild type H3N2 virus for challenge and further
also performing challenge experiments with avian influenza
viruses to assess the breadth of protection afforded by
the adjuvanted vaccines. Another limitation is the fact that
heterologous virus challenge was performed 3 weeks after
the last immunization when adjuvant-induced innate immune
responses might still have been present. However, for CAF09
little induction of (systemic) innate immunity has been
observed (Christensen et al. unpublished observations) while for
CTA1-DD a low level of antigen-independent protection was
observed independent of the time period (2, 4, or 6 weeks)
between immunization and challenge (Lycke et al. unpublished
observations). Thus, while we cannot completely rule out an
effect of adjuvant-induced innate responses we consider it
unlikely that these are the major reason for the observed
cross-protection. Future experiments devoted to assessing the
durability of the induced immune responses by increasing the
period between immunization and challenge will clarify this
point definitely.
The results of our head-to-head comparison of different
vaccines underline that mucosal immunization with adjuvanted
WIV is indeed a promising approach for developing a broadly
protective influenza vaccine. These vaccines induce a plethora
of immune responses including mucosal IgA, cross-reactive
(though not cross-neutralizing) systemic IgG, and CD4 Th
cells. Each of these seems to play a role in cross-protection
but neither appeared to be crucial. This indicates that, several
immune mechanisms contribute to the cross-protection induced
by mucosal vaccination with adjuvanted WIV and optimal
protection thus requires a combination of different mechanisms.
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